ProCE Banner Activity

New Therapeutic Developments in Urothelial Cancer: Clinical Trial Evidence and Expert Guidance

Watch this on-demand Webcast capturing a live CCO Webinar with expert presentations on the evolving care of patients with urothelial cancer, with a focus on immunotherapy.

Released: October 19, 2020

Expiration: October 18, 2021

Share

Faculty

Matthew I. Milowsky

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Jonathan Rosenberg

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by an independent educational grant from Merck & Co., Inc.

Supported by educational grants from

Astellas Seattle Genetics

QED Therapeutics

Faculty Disclosure

Primary Author

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Matthew I. Milowsky, MD, has disclosed that he has received consulting fees from BioClin Therapeutics and funds for research support paid to his institution from Acerta, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cerulean, Clovis, Constellation, Incyte, Innocrin, Inovio, Jounce, MedImmune, Merck, Roche/Genentech, Seattle Genetics, Syndax, and X4 Pharmaceuticals.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Exelixis, Incyte, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and UroGen; has received funds for research support paid to his institution from Ada Cap (Advanced Accelerator Applications), Agensys, Astellas, AstraZeneca, Bayer, BioXcel, Bristol-Myers Squibb, Clovis, Eisai, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi, and Seattle Genetics; and has had ownership interests in Bellicum and Tyme.

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Jonathan E. Rosenberg, MD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Merck, Pharmacyclics, Pfizer, Roche/Genentech, and Seattle Genetics; funds for research support from Astellas, AstraZeneca, Bayer, QED Therapeutics, Seattle Genetics, and Roche/Genentech; and faculty honorarium from Chugai.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.